The FHI Clinical project team has partnered with companies to conduct clinical trials as well as epidemiological and observational studies for tuberculosis in 30 countries worldwide.
The FHI Clinical project team has partnered with companies to conduct clinical trials as well as behavioral and observational studies for HIV in 24 countries worldwide.
For nearly 20 years, the FHI Clinical project team has partnered with companies developing and deploying vaccines, treatments and preventive devices for malaria in 38 countries worldwide.
FHI Clinical has long-standing relationships, a local team and broad expertise in sub-Saharan Africa. We're ready to help you confidently expand your research across the region, finding the best-fit countries and populations for your target indication and study type.
FHI Clinical goes where our expertise is needed. Whether it requires working from a state-of-the-art facility or in a low-tech, rural setting, we provide services tailored to meet your study needs, from protocol design and site assessments to trial planning, implementation and management.
For nearly 20 years, the FHI Clinical project team has partnered with companies developing and deploying vaccines, treatments and diagnostic tests for multiple oncology indications.
Investigating existing treatments for their efficacy to treat COVID-19 is important in some countries with limited access to new treatments, such as Ghana. In this project profile, Loice Magaria, Clinical Research Project Manager at FHI Clinical, discusses a study we’re supporting in Ghana to investigate COVID-19 treatments.
In this video, FHI Clinical experts share their final thoughts following a fall 2021 trip to Liberia to visit the PREVAIL network of sites and staff.
Watch this video to hear FHI Clinical experts detail upcoming research projects the PREVAIL network is excited to embark on, including a Lassa fever program.
FHI Clinical experts discuss their observations on the effects of COVID-19 on the local healthcare system during their fall 2021 visit to the Liberian PREVAIL sites.